FIRST TRACKS BIOTHERAPEUTICS, INC. Expense Breakdown
No Expense Breakdown for TRAX on this site yet.
- 2026-06-30: Anb033 $8.84M; Preclinical and other unallocated costs $4.45M; Rosnilimab $1.22M; Anb101 $687.00K.
- 2025-06-30: Anb033 $3.93M; Preclinical and other unallocated costs $4.46M; Rosnilimab $15.61M; Anb101 $2.04M.
Source checked: the stored Expense Breakdown page for TRAX.
Expenses by product
Research And Development Expense Reversal Excluding Acquired In Process Cost: each quarter (3 month)
| Quarter end | Anb033 | Preclinical and other unallocated costs | Rosnilimab | Anb101 | Anb032 |
|---|
| 2026-06-30 | $8.84M | $4.45M | $1.22M | $687.00K | $5.00K |
|---|
| 2025-06-30 | $3.93M | $4.46M | $15.61M | $2.04M | $108.00K |
|---|
General and Administrative Expense: each quarter (3 month)
| Quarter end | Internal Expense | External Expenses |
|---|
| 2026-06-30 | $9.75M | -$459.00K |
|---|
| 2025-06-30 | $5.17M | $1.45M |
|---|
Research And Development Expense Reversal Including Acquired In Process Cost: each quarter (3 month)
| Quarter end | Internal Expenses |
|---|
| 2026-06-30 | $10.45M |
|---|
| 2025-06-30 | $13.13M |
|---|